Sales of Major Products

(billion yen)

  FY2018 FY2019
XTANDI 333.1 400.0
  United States 164.7 203.5
ex-United States 168.3 196.5
  Japan 32.3 35.8
Establishied Markets 119.0 135.4
Greater China 2.2 3.2
International 14.8 22.1
XOSPATA 2.5 14.3
  Japan 0.6 2.8
United States 2.0 10.5
Establishied Markets 0.9
Betanis/Myrbetriq/BETMIGA 147.2 161.6
  Japan 32.7 34.3
United States 80.8 89.2
Establishied Markets 25.3 28.2
Greater China 1.2 1.4
International 7.2 8.4
Vesicare 95.0 44.7
  Japan 22.3 20.2
United States 36.9 5.4
Establishied Markets 29.4 13.1
Greater China 1.9 1.8
International 4.6 4.2
Prograf 195.7 192.9
  Japan 45.4 44.3
United States 14.0 13.2
Establishied Markets 74.4 71.5
Greater China 31.3 32.2
International 30.5 31.7

 

Sales of products in Japan are shown in a gross sales basis.

 

- Established Markets: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc

 

 

Note:

The data used within this site is compiled from the earnings announcements. Frequency of updates may vary due to changes in earnings report format. For more detailed earnings information, please see the earnings releases. This site will not be immediately updated if correction of earnings data and others are announced. In the preparation of the various data shown within this site, we make every effort to ensure its accuracy. But despite our best efforts, the possibility for inaccuracy in the data due to reasons beyond our control exists. The data contained within this page uses service provided by Nomura Investor Relations Co., Ltd.

Powered by